EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC

Targeted therapies for patients with NSCLC with molecular alterations, including alectinib (a preferred first-line treatment for patients with advanced anaplastic lymphoma kinase [ALK+] NSCLC), are being explored in the adjuvant setting in clinical trials. However, the role of targeted treatments as neoadjuvant therapy for patients with resectable NSCLC remains unclear. NAUTIKA1 (NCT04302025) is an ongoing, phase II umbrella trial investigating the efficacy and safety of targeted therapies as neo(adjuvant) treatment in patients with resectable NSCLC with molecular alterations, including ALK, ROS1, NTRK, BRAF V600, and RET.